BRPI0821474B8 - formulação farmacêutica líquida estável - Google Patents
formulação farmacêutica líquida estávelInfo
- Publication number
- BRPI0821474B8 BRPI0821474B8 BRPI0821474A BRPI0821474A BRPI0821474B8 BR PI0821474 B8 BRPI0821474 B8 BR PI0821474B8 BR PI0821474 A BRPI0821474 A BR PI0821474A BR PI0821474 A BRPI0821474 A BR PI0821474A BR PI0821474 B8 BRPI0821474 B8 BR PI0821474B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical formulation
- liquid pharmaceutical
- stable liquid
- formulations
- stable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1741807P | 2007-12-28 | 2007-12-28 | |
US61/017,418 | 2007-12-28 | ||
US1788107P | 2007-12-31 | 2007-12-31 | |
US61/017,881 | 2007-12-31 | ||
PCT/US2008/088201 WO2009086400A2 (en) | 2007-12-28 | 2008-12-23 | Recombinant vwf formulations |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0821474A2 BRPI0821474A2 (pt) | 2017-05-09 |
BRPI0821474B1 BRPI0821474B1 (pt) | 2021-03-30 |
BRPI0821474B8 true BRPI0821474B8 (pt) | 2021-05-25 |
Family
ID=40591819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0821474A BRPI0821474B8 (pt) | 2007-12-28 | 2008-12-23 | formulação farmacêutica líquida estável |
Country Status (15)
Country | Link |
---|---|
US (2) | US20090192076A1 (pt) |
EP (2) | EP2244814B1 (pt) |
JP (3) | JP5784907B2 (pt) |
KR (2) | KR20160091434A (pt) |
CN (2) | CN105816858A (pt) |
AR (1) | AR069989A1 (pt) |
AU (1) | AU2008345135C1 (pt) |
BR (1) | BRPI0821474B8 (pt) |
CA (1) | CA2710762A1 (pt) |
ES (1) | ES2887187T3 (pt) |
MX (1) | MX2010007150A (pt) |
NZ (1) | NZ586383A (pt) |
SG (2) | SG10201608059VA (pt) |
TW (3) | TWI515006B (pt) |
WO (1) | WO2009086400A2 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8652782B2 (en) * | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
ES2552858T3 (es) | 2007-10-01 | 2015-12-02 | Longhorn Vaccines And Diagnostics, Llc | Recogida de muestras biológicas y sistema de transporte y métodos de uso |
US11197916B2 (en) * | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
TWI515006B (zh) | 2007-12-28 | 2016-01-01 | 巴克斯特國際公司 | 重組vwf調配物 |
BRPI0919693A2 (pt) * | 2008-10-21 | 2020-08-11 | Baxter Healthcare S.A | formulação farmacêutica estável liofilizada |
CA2772051C (en) | 2009-08-24 | 2020-08-18 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
NZ600278A (en) | 2009-11-13 | 2014-04-30 | Grifols Therapeutics Inc | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
CA2785585A1 (en) * | 2009-12-22 | 2011-06-30 | Celldex Therapeutics, Inc. | Vaccine compositions |
TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
KR101969515B1 (ko) * | 2011-06-10 | 2019-04-16 | 박스알타 인코퍼레이티드 | 재조합 vwf의 투여에 의한 응고 질환의 치료 |
HUE046396T2 (hu) | 2012-01-12 | 2020-02-28 | Bioverativ Therapeutics Inc | Kiméra faktor VIII polipeptidek és ezek alkalmazása |
KR102008190B1 (ko) | 2012-02-15 | 2019-08-07 | 바이오버라티브 테라퓨틱스 인크. | 재조합 인자 viii 단백질 |
ES2935489T3 (es) | 2012-02-15 | 2023-03-07 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
JP6603128B2 (ja) | 2012-07-11 | 2019-11-06 | バイオベラティブ セラピューティクス インコーポレイテッド | XTENおよびvonWillebrand因子タンパク質を有する第VIII因子の複合体、および、その使用 |
NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
SG11201605242YA (en) * | 2014-01-10 | 2016-07-28 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
PL3158055T3 (pl) * | 2014-06-13 | 2020-03-31 | Csl Limited | Ulepszone wytwarzanie rekombinowanego czynnika von Willebranda w bioreaktorze |
EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
CN113082349B (zh) | 2016-06-27 | 2023-07-28 | 武田药品工业株式会社 | 注射器稳定装置 |
KR20200037235A (ko) | 2017-07-07 | 2020-04-08 | 박스알타 인코퍼레이티드 | 재조합 vwf의 투여에 의해 중증 폰 빌레브란트 병을 가지고 있는 환자에서 위장 출혈의 치료 |
CN107966567B (zh) * | 2017-11-21 | 2018-12-18 | 浙江夸克生物科技有限公司 | 一种触珠蛋白测定试剂盒 |
CA3094644A1 (en) * | 2018-03-21 | 2019-09-26 | Baxalta Incorporated | Separation of vwf and vwf propeptide by chromatographic methods |
US20230041240A1 (en) * | 2020-01-30 | 2023-02-09 | Leukocare Ag | Reduction of Adsorption |
CN115666522A (zh) * | 2020-03-18 | 2023-01-31 | Gi医诺微新 | 包含il-2蛋白和cd80蛋白的融合蛋白制剂 |
WO2023170680A1 (en) | 2022-03-08 | 2023-09-14 | Equashield Medical Ltd | Fluid transfer station in a robotic pharmaceutical preparation system |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA7972A (en) * | 1877-10-05 | Edward M. Lowdon | Improvements in lamps | |
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
AU591671B2 (en) | 1985-04-11 | 1989-12-14 | Children's Medical Center Corporation | Von willebrand factor |
US5900476A (en) * | 1986-05-30 | 1999-05-04 | The Scripps Research Institute | Therapeutic domains of van Willebrand factor |
US5847086A (en) * | 1991-06-20 | 1998-12-08 | Centeon L.L.C. | Therapeutic fragments of von Willebrand factor |
WO1993000107A1 (en) * | 1991-06-20 | 1993-01-07 | Rhone-Poulenc Rorer International (Holdings) Inc. | Therapeutic fragments of von willebrand factor |
US5670132A (en) * | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
DE4435392B4 (de) * | 1994-10-04 | 2008-02-07 | Immuno Ag | Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF |
DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
US20010046487A1 (en) * | 1994-12-30 | 2001-11-29 | Roser Bruce J. | Methods for loading platelets, stabilizing platelets for dry storage and compositions obtained thereby |
US7253262B2 (en) * | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
US7244824B2 (en) * | 1995-01-19 | 2007-07-17 | Quadrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
PT1516628E (pt) | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6005077A (en) * | 1995-11-10 | 1999-12-21 | Immuno Aktiengesellschaft | Use of von willebrand factor and pharmaceutical formulation |
US5925738A (en) * | 1995-12-01 | 1999-07-20 | The American National Red Cross | Methods of production and use of liquid formulations of plasma proteins |
AU3671197A (en) | 1996-07-19 | 1998-02-10 | Regents Of The University Of Michigan, The | Dna encoding canine von willebrand factor and methods of use |
SE9604296D0 (sv) | 1996-11-22 | 1996-11-22 | Astra Ab | New pharmaceutical formulation of polypeptides |
AT405403B (de) * | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
AT405485B (de) | 1997-05-28 | 1999-08-25 | Immuno Ag | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
US6005007A (en) * | 1997-07-18 | 1999-12-21 | Farmer; Luc J. | Retinoids, methods for their production and use |
US6310183B1 (en) * | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
FR2772381B1 (fr) | 1997-12-15 | 2001-06-08 | Lab Francais Du Fractionnement | Procede de preparation par filtration d'une solution de facteur viii securisee viralement |
US6531577B1 (en) * | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
EP1148063A1 (de) * | 2000-04-18 | 2001-10-24 | Octapharma AG | Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung |
EP1314437B1 (en) | 2000-08-11 | 2014-06-25 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
DE10043124A1 (de) * | 2000-08-31 | 2002-03-14 | Max Delbrueck Centrum | Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase |
HUP0301245A3 (en) | 2000-10-02 | 2005-12-28 | Novo Nordisk Healthcare Ag | Tmethod for the production of vitamin k-dependent proteins |
EP1324776B2 (en) * | 2000-10-12 | 2018-03-21 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
ES2363205T3 (es) | 2002-06-21 | 2011-07-26 | Novo Nordisk Health Care Ag | Glicoformas del factor vii pegilado. |
AU2003291689A1 (en) | 2002-10-31 | 2004-05-25 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
AU2004204262B2 (en) * | 2003-01-10 | 2010-11-04 | Ablynx N.V. | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen |
ES2229931B1 (es) | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
FR2861395B1 (fr) | 2003-10-23 | 2006-02-17 | Lab Francais Du Fractionnement | Facteur viii viralement securise a faible teneur en multimeres superieurs |
TR201809670T4 (tr) * | 2003-12-19 | 2018-07-23 | Novo Nordisk Healthcare Ag | Faktör VII polipeptitlerinin stabilize edilmiş kompozisyonları. |
US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
FR2874216B1 (fr) | 2004-08-16 | 2006-11-03 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu |
DE102004044421B4 (de) * | 2004-09-14 | 2010-06-24 | Biotest Ag | Verfahren zur Trennung eines von Willebrand Faktors mit einer spezifischen VWF-Aktivität von wenigstens 50 E/mg VWF-Antigen von einem von Willebrand Faktor mit niedriger Aktivität und Verwendung von Hydroxylapatit dafür |
KR20070092754A (ko) | 2004-12-27 | 2007-09-13 | 백스터 인터내셔널 인코포레이티드 | 중합체 - 폰 빌레브란트 인자 - 접합체 |
EP1707634A1 (en) * | 2005-03-29 | 2006-10-04 | Octapharma AG | Method for isolation of recombinantly produced proteins |
GB0509443D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbents for factor VIII and von willebrand's factor |
EP2264162A1 (en) * | 2005-07-02 | 2010-12-22 | Arecor Limited | Stable aqueous systems comprising proteins |
US7956160B2 (en) * | 2005-07-22 | 2011-06-07 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
EP1986612B1 (en) * | 2006-02-07 | 2012-09-12 | Shire Human Genetic Therapies, Inc. | Stabilized composition of glucocerebrosidase |
WO2008015187A1 (en) | 2006-08-01 | 2008-02-07 | Telefonaktiebolaget Lm Ericsson (Publ) | User preferences in interactive personal television |
GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
WO2008127654A2 (en) * | 2007-04-11 | 2008-10-23 | The University Of North Carolina At Chapel Hill | Methods and compositions for intra-articular coagulation proteins |
MX2009011367A (es) * | 2007-04-26 | 2010-03-22 | Bayer Healthcare Llc | Estabilizacion de soluciones liquidas de proteina recombinante para el almacenamiento congelado. |
CA2690218C (en) | 2007-06-13 | 2017-02-28 | Csl Behring Gmbh | Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders |
FR2920429B1 (fr) * | 2007-08-30 | 2012-10-05 | Lfb Biotechnologies | Procede de purification du facteur viii et du facteur von willebrand |
TWI515006B (zh) | 2007-12-28 | 2016-01-01 | 巴克斯特國際公司 | 重組vwf調配物 |
ES2298096B1 (es) * | 2008-01-08 | 2009-01-01 | Grifols, S.A. | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
DE102008032361A1 (de) * | 2008-07-10 | 2010-01-21 | Csl Behring Gmbh | Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie |
CA2738715C (en) * | 2008-10-15 | 2013-07-16 | Intarcia Therapeutics, Inc. | Highly concentrated drug particles, formulations, suspensions and uses thereof |
KR20110093775A (ko) * | 2008-11-03 | 2011-08-18 | 바이엘 헬스케어 엘엘씨 | 혈우병 치료 방법 |
JP5866203B2 (ja) * | 2009-02-05 | 2016-02-17 | ピエール フィリッパール, | 組織産生のための方法および手段ならびに得られる組織 |
-
2008
- 2008-12-23 TW TW097150160A patent/TWI515006B/zh active
- 2008-12-23 US US12/342,646 patent/US20090192076A1/en not_active Abandoned
- 2008-12-23 CA CA2710762A patent/CA2710762A1/en not_active Abandoned
- 2008-12-23 TW TW103123730A patent/TWI600437B/zh active
- 2008-12-23 KR KR1020167019749A patent/KR20160091434A/ko not_active Application Discontinuation
- 2008-12-23 AR ARP080105733A patent/AR069989A1/es not_active Application Discontinuation
- 2008-12-23 NZ NZ586383A patent/NZ586383A/xx unknown
- 2008-12-23 MX MX2010007150A patent/MX2010007150A/es active IP Right Grant
- 2008-12-23 CN CN201610221805.8A patent/CN105816858A/zh active Pending
- 2008-12-23 SG SG10201608059VA patent/SG10201608059VA/en unknown
- 2008-12-23 EP EP08866246.5A patent/EP2244814B1/en active Active
- 2008-12-23 WO PCT/US2008/088201 patent/WO2009086400A2/en active Application Filing
- 2008-12-23 SG SG2012096343A patent/SG187410A1/en unknown
- 2008-12-23 JP JP2010540873A patent/JP5784907B2/ja active Active
- 2008-12-23 AU AU2008345135A patent/AU2008345135C1/en active Active
- 2008-12-23 KR KR1020107015467A patent/KR101643277B1/ko active IP Right Review Request
- 2008-12-23 BR BRPI0821474A patent/BRPI0821474B8/pt active IP Right Grant
- 2008-12-23 TW TW106116319A patent/TW201731488A/zh unknown
- 2008-12-23 CN CN2008801273390A patent/CN101952016A/zh active Pending
- 2008-12-23 ES ES08866246T patent/ES2887187T3/es active Active
- 2008-12-23 EP EP21177089.6A patent/EP3936116A1/en active Pending
-
2014
- 2014-05-29 JP JP2014111341A patent/JP2014159479A/ja not_active Withdrawn
-
2015
- 2015-04-22 US US14/693,078 patent/US11191837B2/en active Active
-
2016
- 2016-06-06 JP JP2016112428A patent/JP2016164199A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0821474B8 (pt) | formulação farmacêutica líquida estável | |
CY1118038T1 (el) | Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος | |
BR112015023391A2 (pt) | formulações compreendendo conjugado droga-anticorpo anti-egfr | |
WO2010048275A3 (en) | Lyophilized recombinant vwf formulations | |
CU20060153A7 (es) | Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen | |
UY30319A1 (es) | Formulaciones de inhibidores de dpp iv | |
GT200900057A (es) | 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato | |
BRPI0820535A8 (pt) | composições farmacêuticas contendo insulina e um peptídeo insulinotrópico | |
NI201000193A (es) | Formulaciones orales de análogos de citidina y métodos de uso de las mismas. | |
CR20110110A (es) | Composicion farmaceutica | |
EP1948271A4 (en) | DISTRACTION OF VISCOUS FORMULATIONS BY NADELLOSIS INJECTION | |
BRPI0913379A2 (pt) | formulações farmacêuticas sólidas compreendendo bibw 2992 | |
BRPI0809667A2 (pt) | Composto, medicamento e composição farmacêutica que o contém e uso do composto | |
BRPI0808293A2 (pt) | "composições para administração nasal" | |
SV2009003335A (es) | Formulaciones para el cancer | |
CY1110221T1 (el) | Σταθερα φαρμακευτικα σκευασματα νατριουχου μοντελουκαστης | |
WO2008066899A3 (en) | Nanoparticulate formulations and methods for the making and use thereof | |
BR112014011841A2 (pt) | material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos | |
ECSP077238A (es) | Composiciones para entrega de drogas altamente solubles en agua | |
CL2007001869A1 (es) | Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e | |
BR112015000203A2 (pt) | formulações de etanercept que exibem redução marcada em partículas sub-visíveis | |
BR112013008601A8 (pt) | Formulações de emulsão de clevidipina contendo agentes antimicrobianos | |
BR112012012969A2 (pt) | '' formulação farmacêutica líquida e uso de um antioxidante'' | |
CR10124A (es) | Formulaciones orales que comprenden tigeciclina | |
CO6280503A2 (es) | Conjugados de neurturina novedosas para uso farmaceutico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority | ||
B25A | Requested transfer of rights approved |
Owner name: BAXALTA GMBH (CH) , BAXALTA INCORPORATED (US) |
|
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |